MSLN and acute myeloid leukemia: To establish the influence of mesothelin on AML, the KG1α AML cell line was treated with 0.25 μg/mL or 0.5 μg/mL recombinant human (rh) mesothelin peptide (rhMesothelin) for 1 h.